[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
October 20, 1999

Incorrect Information

JAMA. 1999;282(15):1425. doi:10.1001/jama.282.15.1425

In the Medical News & Perspectives article entitled "FDA Weighs Communicating Drug-Related Risk to Patients" published in the August 11, 1999, issue of THE JOURNAL (1999;282:515), the words "troglitazone (Rezulin, used for type 2 diabetes)" should be deleted. No written informed consent has been recommended or advised in connection with the prescription of this drug.

×